Cardioreparation in hypertensive heart disease

Area of Science:

• Cardiology
• Cardiovascular Physiology
• Pathology

Background:

• Normal myocardium comprises myocytes and non-cardiomyocytes within an extracellular matrix.
• Ventricular hypertrophy involves myocyte growth, while hypertensive heart disease (HHD) includes both myocyte and nonmyocyte growth.
• HHD leads to adverse structural remodeling of coronary vasculature and matrix, impacting myocardial quality and increasing cardiovascular event risk.

Purpose of the Study:

• To highlight the importance of targeting adverse structural remodeling in hypertensive heart disease (HHD).
• To emphasize that myocardial quality, not just quantity, dictates cardiovascular event risk in HHD.
• To discuss the role of cardioprotective and cardioreparative agents in managing HHD.

Main Methods:

• Review of the physiological mechanisms underlying myocardial structure and remodeling in HHD.
• Analysis of the balance between stimulatory and inhibitory signals regulating cardiac cell growth and matrix turnover.
• Evaluation of the therapeutic potential of pharmacological interventions, including ACE inhibitors.

Main Results:

• Hypertensive heart disease (HHD) is characterized by adverse structural remodeling of the heart, affecting both cellular and matrix components.
• The equilibrium between stimulatory and inhibitory signaling pathways is disrupted in HHD, promoting pathological growth and remodeling.
• Pharmacological interventions, particularly ACE inhibition, demonstrate efficacy in reversing structural abnormalities and improving cardiac function.

Conclusions:

• Effective management of hypertension requires addressing not only blood pressure but also the underlying adverse structural remodeling.
• Cardioprotective and cardioreparative agents are essential for counteracting the detrimental effects of HHD.
• Targeting structural remodeling offers a promising strategy to reduce the risk of heart failure and sudden cardiac death in patients with HHD.